TL;DR: Aetna, a CVS Health company, modified CPB 0760 covering oral screening and lesion identification systems, effective December 3, 2025. Every major technology in this space — AI-based tools, HPV testing, fluorescence imaging, and salivary biomarkers — is classified as experimental and non-covered. Here's what that means for oral screening billing.
If your dental or ENT billing team has been submitting claims for oral cancer screening adjuncts under Aetna, this update cements what many suspected: Aetna's oral screening coverage policy leaves almost no room for reimbursement on these technologies. CPT codes 87623, 87624, 87625, and 87626 for HPV nucleic acid detection, HCPCS code D0431 for adjunctive pre-diagnostic testing, and CPT 86663–86665 for Epstein-Barr virus antibody testing are all explicitly non-covered under this policy. The effective date is December 3, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Oral Screening and Lesion Identification Systems |
| Policy Code | CPB 0760 |
| Change Type | Modified |
| Effective Date | December 3, 2025 |
| Impact Level | High |
| Specialties Affected | Oral surgery, dentistry, ENT, head and neck oncology, pathology |
| Key Action | Audit all oral screening claims billed to Aetna and stop submitting non-covered codes effective December 3, 2025 |
Aetna Oral Screening Coverage Criteria and Medical Necessity Requirements 2025
Under CPB 0760 Aetna's framework, there are no covered indications for oral screening and lesion identification technologies. This is not a policy with a covered tier and an excluded tier. The entire category is experimental, investigational, or unproven.
That's the real issue here. This isn't a narrow exclusion of one fringe technology. Aetna draws the line at every tool your clinical team might reach for — from widely marketed products like VELscope and ViziLite to newer molecular approaches like salivary microRNA testing and tumor-derived exosomal biomarkers. Medical necessity cannot be established under this policy because no indication qualifies.
If you've been billing D0431 for adjunctive pre-diagnostic oral cancer screening and expecting Aetna reimbursement, this policy makes the payer's position explicit. The same goes for HCPCS code G0476 for high-risk HPV nucleic acid detection — non-covered, full stop. Prior authorization won't change that outcome. There's no pathway through prior auth because coverage itself is denied at the policy level.
Talk to your compliance officer before December 3, 2025 if your practice has recurring Aetna claims in this category. The financial exposure from continued billing after the effective date is real.
Aetna Oral Screening Exclusions and Non-Covered Indications
This section is where CPB 0760 does all of its work. Aetna classifies the following as experimental, investigational, or unproven:
AI and emerging biomarker technologies:
Artificial intelligence-based oral screening tools have no covered pathway under this policy. That includes any AI-assisted lesion detection platform, regardless of FDA clearance status. Salivary biomarkers — including DUSP100, IL-1B, IL-8, MMP-9, microRNA, mRNA, s100P, and TNF-alpha — are excluded for screening and detection of oral squamous cell carcinoma. Salivary hyper-methylated DNA biomarkers and salivary metabolite biomarkers for oral squamous cell carcinoma and oral epithelial dysplasia are also excluded.
Tumor-derived exosomal (TEX) biomarkers from liquid biopsy for early oral cancer detection fall in the same bucket. This is a sweeping exclusion of the entire liquid biopsy approach for this indication.
Viral testing:
Epstein-Barr virus (EBV) testing for oral squamous cell carcinoma screening — billed under CPT 86663, 86664, or 86665 — is non-covered. Oral HPV testing, including the OraRisk HPV Salivary DNA Test and related assays billed under CPT 87623, 87624, 87625, or 87626, is non-covered for all indications. Not just screening — all indications.
Optical and imaging-based technologies:
This is where the list gets long. Aetna excludes all of the following for early detection of oral cancer and other indications:
| # | Excluded Procedure |
|---|---|
| 1 | Chemiluminescence (CPT 82397) |
| 2 | Confocal laser endomicroscopy |
| 3 | Diffuse reflectance spectroscopy |
| 4 | Fluorescence spectroscopy |
| 5 | MOP genetic testing |
| 6 | Narrow band imaging |
| 7 | Optical filter for auto-fluorescence — including GOCCLES (Glasses for Oral Cancer Curing Light Exposed) |
| 8 | Optical fluorescence imaging, including 5-aminolevulinic acid induced protoporphyrin IX fluorescence and auto-fluorescence |
| 9 | Oral lesion identification systems: Dentlight Oral Exam Light Kit, Microlux DL, Orascoptic DK, Sapphire Plus, TRIMIRA Identafi 3000, ViziLite-Blue, and VELscope |
| 10 | Straticyte |
| 11 | Wide-field and high-resolution in-vivo imaging |
If your practice has invested in any of these systems and been billing for them under Aetna, the claim denial risk is high. Unlisted procedure codes 40899, 41599, and 41899 used to report these services also fall under the non-covered group.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| AI-based oral cancer screening | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| EBV testing for oral squamous cell carcinoma screening | Not Covered | 86663, 86664, 86665 | Explicitly excluded |
| Oral HPV testing (all indications) | Not Covered | 0429U, 87623, 87624, 87625, 87626, G0476 | Excludes all indications, not just screening |
| Salivary biomarkers (DUSP100, IL-1B, IL-8, MMP-9, microRNA, mRNA, s100P, TNF-alpha) | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| Salivary hyper-methylated DNA biomarkers | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| Salivary metabolite biomarkers | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| TEX biomarkers / liquid biopsy for oral cancer | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| Chemiluminescence | Not Covered / Experimental | 82397 | All indications excluded |
| Optical fluorescence imaging (VELscope, ViziLite, etc.) | Not Covered / Experimental | D0431, 40899, 41599, 41899 | Named devices listed explicitly |
| Straticyte | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| Confocal laser endomicroscopy | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| Narrow band imaging | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| Wide-field and high-resolution in-vivo imaging | Not Covered / Experimental | 40899, 41599, 41899 | No covered pathway |
| Adjunctive pre-diagnostic oral cancer screening | Not Covered | D0431 | Dental HCPCS, explicitly excluded |
| High-risk HPV nucleic acid detection (Medicare context) | Not Covered | G0476 | Non-covered under Aetna CPB 0760 |
Aetna Oral Screening Billing Guidelines and Action Items 2025
This policy is clear, so the action items are straightforward. The billing guidelines here aren't about finding workarounds — they're about protecting your revenue cycle from unnecessary denials.
| # | Action Item |
|---|---|
| 1 | Pull all Aetna oral screening claims from the last 12 months. Look for CPT codes 86663, 86664, 86665, 87623, 87624, 87625, 87626, 82397, 0429U, and HCPCS codes D0431 and G0476. Also flag unlisted procedure codes 40899, 41599, and 41899 used for optical or fluorescence-based services. Any of these billed to Aetna are at risk. |
| 2 | Stop submitting non-covered codes to Aetna effective December 3, 2025. The effective date is not a grace period. Claims submitted after December 3, 2025 for these services will deny. Remove them from your Aetna charge capture now. |
| 3 | Review your ABN process for affected patients. If your practice offers any of these technologies and patients have Aetna coverage, you need an Advance Beneficiary Notice equivalent — a financial agreement — before providing the service. Patients who want these tests need to know up front they'll pay out of pocket under Aetna plans. |
| 4 | Check related policy CPB 0686. Aetna cross-references CPB 0686 for oral and esophageal brush biopsy. If your team bills for brush biopsy services, confirm that coding pathway separately. Don't assume CPB 0760's exclusions affect brush biopsy coverage — but verify. |
| 5 | Don't rely on unlisted procedure codes as a workaround. Some billing teams use codes like 41899 hoping to get a manual review. Under CPB 0760, Aetna has explicitly grouped unlisted procedure codes with the non-covered technologies. Manual review won't produce a different outcome here. |
| 6 | Loop in your compliance officer if your volume is significant. If your practice has been billing these codes regularly to Aetna and receiving payment, you may have an overpayment exposure issue. That's a conversation for your compliance officer, not your billing team alone. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Oral Screening Under CPB 0760
Not Covered CPT Codes — Epstein-Barr Virus Testing
| Code | Type | Description | Reason |
|---|---|---|---|
| 86663 | CPT | Antibody; Epstein-Barr (EB) virus | Not covered for indications listed in CPB 0760 |
| 86664 | CPT | Antibody; Epstein-Barr (EB) virus | Not covered for indications listed in CPB 0760 |
| 86665 | CPT | Antibody; Epstein-Barr (EB) virus | Not covered for indications listed in CPB 0760 |
Not Covered CPT Codes — HPV, Optical, and Unlisted Procedures
| Code | Type | Description | Reason |
|---|---|---|---|
| 0429U | CPT (PLA) | Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (16, 18, 31, 33, 35, 39, 45, and others) | Non-covered: HPV testing, optical fluorescence, salivary biomarkers group |
| 40899 | CPT | Unlisted procedure, vestibule of mouth | Non-covered: MicroRNAs, Straticyte, optical fluorescence imaging, salivary biomarkers group |
| 41599 | CPT | Unlisted procedure, tongue, floor of mouth | Non-covered: MicroRNAs, Straticyte, optical fluorescence imaging, salivary biomarkers group |
| 41899 | CPT | Unlisted procedure, dentoalveolar structures | Non-covered: MicroRNAs, Straticyte, optical fluorescence imaging, salivary biomarkers group |
| 82397 | CPT | Chemiluminescent assay | Non-covered: chemiluminescence group |
| 87623 | CPT | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types | Non-covered: HPV testing group |
| 87624 | CPT | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types | Non-covered: HPV testing group |
| 87625 | CPT | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 | Non-covered: HPV testing group |
| 87626 | CPT | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported | Non-covered: HPV testing group |
Not Covered HCPCS Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| D0431 | HCPCS | Adjunctive pre-diagnostic test that aids in detection of mucosal abnormalities including premalignant and malignant lesions | Not covered for indications listed in CPB 0760 |
| G0476 | HCPCS | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types | Not covered for indications listed in CPB 0760 |
Key ICD-10-CM Diagnosis Codes Referenced in CPB 0760
These diagnosis codes appear in the policy. Their presence doesn't create a covered pathway — they're listed as context for the indications the policy addresses.
| Code | Description |
|---|---|
| A69.0 | Disease of oral cavity, salivary glands, and jaws |
| C00.0–C10.9 | Malignant neoplasm of lip and oral cavity |
| D00.0–D00.8 | Carcinoma in situ of lip, oral cavity, and pharynx |
| D37.01–D37.02, D37.04–D37.09 | Neoplasm of uncertain behavior of lip, oral cavity, and pharynx |
| K00.0–K14.9 | Disease of oral cavity, salivary glands, and jaws |
| Z12.81 | Encounter for screening for malignant neoplasms of oral cavity |
Note on Z12.81: This is the screening encounter code for oral cavity malignancy. Its presence in the policy reinforces that Aetna reviewed this code category — and still classified every listed screening technology as non-covered. Pairing Z12.81 with D0431 or any optical screening code won't create a covered claim.
Get the Full Picture for CPT 86663
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.